474 related articles for article (PubMed ID: 34593302)
41. Generation of 17q21.31 duplication iPSC-derived neurons as a model for primary tauopathies.
Miguel L; Rovelet-Lecrux A; Chambon P; Joly-Helas G; Rousseau S; Wallon D; Epelbaum S; Frébourg T; Campion D; Nicolas G; Lecourtois M
Stem Cell Res; 2022 May; 61():102762. PubMed ID: 35358831
[TBL] [Abstract][Full Text] [Related]
42. MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies.
Trabzuni D; Wray S; Vandrovcova J; Ramasamy A; Walker R; Smith C; Luk C; Gibbs JR; Dillman A; Hernandez DG; Arepalli S; Singleton AB; Cookson MR; Pittman AM; de Silva R; Weale ME; Hardy J; Ryten M
Hum Mol Genet; 2012 Sep; 21(18):4094-103. PubMed ID: 22723018
[TBL] [Abstract][Full Text] [Related]
43. Tau in neurodegenerative disease.
Gao YL; Wang N; Sun FR; Cao XP; Zhang W; Yu JT
Ann Transl Med; 2018 May; 6(10):175. PubMed ID: 29951497
[TBL] [Abstract][Full Text] [Related]
44. Cell-to-Cell Transmission of Tau and α-Synuclein.
Uemura N; Uemura MT; Luk KC; Lee VM; Trojanowski JQ
Trends Mol Med; 2020 Oct; 26(10):936-952. PubMed ID: 32371172
[TBL] [Abstract][Full Text] [Related]
45. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
46. Frontotemporal dementia with the V337M
Spina S; Schonhaut DR; Boeve BF; Seeley WW; Ossenkoppele R; O'Neil JP; Lazaris A; Rosen HJ; Boxer AL; Perry DC; Miller BL; Dickson DW; Parisi JE; Jagust WJ; Murray ME; Rabinovici GD
Neurology; 2017 Feb; 88(8):758-766. PubMed ID: 28130473
[TBL] [Abstract][Full Text] [Related]
47. Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.
Cortés N; Andrade V; Guzmán-Martínez L; Estrella M; Maccioni RB
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29570615
[TBL] [Abstract][Full Text] [Related]
48. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
[TBL] [Abstract][Full Text] [Related]
49. Regulation of alternative splicing of tau exon 10.
Qian W; Liu F
Neurosci Bull; 2014 Apr; 30(2):367-77. PubMed ID: 24627328
[TBL] [Abstract][Full Text] [Related]
50. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
Hasegawa M
Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
[TBL] [Abstract][Full Text] [Related]
51. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
52. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.
Li X; James S; Lei P
J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562
[TBL] [Abstract][Full Text] [Related]
53. The role of MAPT sequence variation in mechanisms of disease susceptibility.
Caffrey TM; Wade-Martins R
Biochem Soc Trans; 2012 Aug; 40(4):687-92. PubMed ID: 22817717
[TBL] [Abstract][Full Text] [Related]
54. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
[TBL] [Abstract][Full Text] [Related]
55. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
56. Mutation screening of the tau gene in patients with early-onset Alzheimer's disease.
Roks G; Dermaut B; Heutink P; Julliams A; Backhovens H; Van de Broeck M; Serneels S; Hofman A; Van Broeckhoven C; van Duijn CM; Cruts M
Neurosci Lett; 1999 Dec; 277(2):137-9. PubMed ID: 10624829
[TBL] [Abstract][Full Text] [Related]
57. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
Alavi Naini SM; Soussi-Yanicostas N
Oxid Med Cell Longev; 2015; 2015():151979. PubMed ID: 26576216
[TBL] [Abstract][Full Text] [Related]
58. Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation.
Su Y; Fu J; Yu J; Zhao Q; Guan Y; Zuo C; Li M; Tan H; Cheng X
J Alzheimers Dis; 2020; 76(1):149-157. PubMed ID: 32444551
[TBL] [Abstract][Full Text] [Related]
59. Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia.
Laws SM; Perneczky R; Drzezga A; Diehl-Schmid J; Ibach B; Bäuml J; Eisele T; Förstl H; Kurz A; Riemenschneider M
Am J Psychiatry; 2007 Oct; 164(10):1577-84. PubMed ID: 17898350
[TBL] [Abstract][Full Text] [Related]
60. Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.
Roy B; Jackson GR
Hum Mol Genet; 2014 Jun; 23(11):3008-23. PubMed ID: 24430504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
